Oxcarbazepine

Evidence Level: L4

Predicted Indications: 1

Oxcarbazepine

Pharmacist Assessment Report

Oxcarbazepine: Restless legs syndrome

One-Sentence Summary

Oxcarbazepine is an antiseizure medicine originally used to treat partial (focal) epilepsy. The TxGNN model predicts it may be effective for restless legs syndrome, but there are no registered clinical trials and the 16 publications retrieved are mostly general antiseizure medication reviews, so evidence specific to this indication is very limited.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Restless legs syndrome
TxGNN Prediction Score	0.9989
Evidence Level	L4
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data are not available in the data compiled for this report. From the retrieved literature, oxcarbazepine acts mainly through its active metabolite, a monohydroxy derivative (MHD). It is understood to block voltage-gated sodium channels and limit repetitive neuronal firing, and it is established for partial-onset seizures.

Visually triggered (photosensitive) epilepsy can include focal features, so there is a plausible mechanistic overlap with the original indication. The prediction therefore appears to reflect a shared focal-seizure mechanism.

There are important caveats. The retrieved papers are general antiseizure medication reviews and guidelines, and none evaluates oxcarbazepine in visually induced seizures. Photosensitive generalised epilepsies are typically treated with valproate, levetiracetam or lamotrigine. Sodium channel blockers may aggravate some generalised syndromes.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

The retrieved items are general epilepsy references. None directly tests oxcarbazepine in visual epilepsy.

PMID	Year	Type	Journal	Key Findings
35380580	2022	Review	JAMA	Overview of antiseizure medications for adults with epilepsy
29898971	2018	Guideline	Neurology	AAN/AES guideline update on newer antiepileptic drugs in new-onset epilepsy
33334546	2020	Review	Seizure	Current role of carbamazepine and oxcarbazepine in epilepsy management
39899099	2025	Review	Continuum	Update on antiseizure medications, covering pharmacokinetics, indications and use
11772334	2002	Review	Expert Opin Pharmacother	Efficacy in partial-onset seizures and trigeminal neuralgia; early signals in other neuropathic pain and bipolar disorders
1379159	1992	Review	Drugs	Pharmacology of oxcarbazepine as the 10-keto analogue of carbamazepine
17560495	2007	Review	Pediatr Neurol	Visual adverse effects of antiepileptic drugs (relates to drug-induced visual disturbance, not treatment of visual epilepsy)

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 13935K	Trileptal	Tablet 600 mg (oral)	Not available in the data compiled for this report

Safety Considerations

Knowledge-graph contraindication signals (from drug-disease relationships, not product label text): anxiety disorder, neurotic disorder, dysthymic disorder, impaired renal function, inappropriate ADH syndrome (hyponatraemia-related), and nephrogenic syndrome of inappropriate antidiuresis.

Drug interactions: The interaction screen returned 100 interactions. The 20 listed were all of Moderate severity, including hydrocortisone, dexamethasone, betamethasone, triamcinolone, cholecalciferol, calcifediol, calcitriol, pioglitazone, saxagliptin, linagliptin, chlorpropamide, aprepitant, morphine, omeprazole, dexlansoprazole, clarithromycin, difenoxin, diphenoxylate, dronabinol and eliglustat.

Seizure aggravation: The retrieved literature includes a case report of oxcarbazepine-induced myoclonic status epilepticus in juvenile myoclonic epilepsy. Sodium channel blockers may worsen generalised epilepsy syndromes, which is relevant to photosensitive epilepsy.

Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications.

Other Predicted Indications (for context)

Predicted Indication	Score	Evidence Level	Evidence Summary	Decision
Restless legs syndrome	0.9989	L4	Three case reports and a narrative review (e.g. PMID 19483488, PMID 16675374); no controlled data	Research question

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests on a plausible shared focal-seizure mechanism, but there are no clinical trials and no literature testing oxcarbazepine in visually triggered seizures. Sodium channel blockade may aggravate some photosensitive generalised syndromes, and established alternatives exist.

To proceed, the following is needed:

Indication-specific clinical data (case series or controlled studies) in visually triggered epilepsy, with seizure syndrome classification (focal versus generalised)
Detailed mechanism of action data
Product Information warnings and contraindications for the registered Australian product, and its approved indication text
A safety plan addressing seizure aggravation risk, hyponatraemia, renal impairment and the interactions above
If a repurposing programme is pursued, consider restless legs syndrome as the more evidence-supported secondary candidate, although it is still limited to case reports
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.